Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy
Charlie Gourley, Judith Balmañà, Jonathan A. Ledermann, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 25, pp. 2257-2269
Open Access | Times Cited: 172

Showing 1-25 of 172 citing articles:

Targeting DNA damage response pathways in cancer
Florian J. Groelly, Matthew Fawkes, Rebecca A. Dagg, et al.
Nature reviews. Cancer (2022) Vol. 23, Iss. 2, pp. 78-94
Closed Access | Times Cited: 446
PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells
Sylvie M. Noordermeer, Haico van Attikum
Trends in Cell Biology (2019) Vol. 29, Iss. 10, pp. 820-834
Open Access | Times Cited: 374
Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook
Lena Horvath, Bernard Thienpont, Liyun Zhao, et al.
Molecular Cancer (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 199
PARP Inhibition in Cancer: An Update on Clinical Development
Esha Sachdev, Roya Tabatabai, Varun Yadav Roy, et al.
Targeted Oncology (2019) Vol. 14, Iss. 6, pp. 657-679
Closed Access | Times Cited: 155
Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification
Bowen Li, Jingwen Jiang, Yehuda G. Assaraf, et al.
Drug Resistance Updates (2020) Vol. 53, pp. 100720-100720
Closed Access | Times Cited: 141
The systemic treatment of recurrent ovarian cancer revisited
Thaïs Baert, Annamaria Ferrero, Jalid Sehouli, et al.
Annals of Oncology (2021) Vol. 32, Iss. 6, pp. 710-725
Open Access | Times Cited: 110
Small molecule inhibitors targeting the cancers
Guihong Liu, Tao Chen, Xin Zhang, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 89
DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities
Dana Jurkovičová, Christiana M. Neophytou, Ana Čipak Gašparović, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 14672-14672
Open Access | Times Cited: 78
Radiation-induced tumor immune microenvironments and potential targets for combination therapy
Siyu Guo, Yihan Yao, Yang Tang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 69
Revolutionizing DNA repair research and cancer therapy with CRISPR–Cas screens
Samah W. Awwad, Almudena Serrano-Benítez, John C. Thomas, et al.
Nature Reviews Molecular Cell Biology (2023) Vol. 24, Iss. 7, pp. 477-494
Closed Access | Times Cited: 48
AXL in cancer: a modulator of drug resistance and therapeutic target
Yaoxiang Tang, Hongjing Zang, Qiuyuan Wen, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 47
Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation
Win Topatana, Sarun Juengpanich, Shijie Li, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 134
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)
Peter A. Fasching, Theresa Link, Jan Hauke, et al.
Annals of Oncology (2020) Vol. 32, Iss. 1, pp. 49-57
Open Access | Times Cited: 118
Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD
Graeme Hewitt, Valérie Borel, Sandra Segura‐Bayona, et al.
Molecular Cell (2020) Vol. 81, Iss. 4, pp. 767-783.e11
Open Access | Times Cited: 112
Apigenin as Tumor Suppressor in Cancers: Biotherapeutic Activity, Nanodelivery, and Mechanisms With Emphasis on Pancreatic Cancer
Milad Ashrafizadeh, Mohammad Reza Bakhoda, Zahra Bahmanpour, et al.
Frontiers in Chemistry (2020) Vol. 8
Open Access | Times Cited: 92
Mesothelin-Specific CAR T Cells Target Ovarian Cancer
Esther Schoutrop, Ibrahim El‐Serafi, Thomas Poiret, et al.
Cancer Research (2021) Vol. 81, Iss. 11, pp. 3022-3035
Open Access | Times Cited: 67
Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer
Mohamed A. Ghonim, Salomè V. Ibba, Abdelmetalab Tarhuni, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 1, pp. e001643-e001643
Open Access | Times Cited: 62
Therapeutic advances in leiomyosarcoma
Kristine Peregrino Lacuna, Sminu Bose, Matthew Ingham, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 24
Small molecule agents for triple negative breast cancer: Current status and future prospects
Yan Ou, Mengchao Wang, Qian Xu, et al.
Translational Oncology (2024) Vol. 41, pp. 101893-101893
Open Access | Times Cited: 13
STK19 is a DNA/RNA-binding protein critical for DNA damage repair and cell proliferation
Y Li, Yanqiu Gong, Yue Zhou, et al.
The Journal of Cell Biology (2024) Vol. 223, Iss. 2
Open Access | Times Cited: 12
Discovery of a small-molecule inhibitor that traps Polθ on DNA and synergizes with PARP inhibitors
William Fried, Mrityunjay Tyagi, Leonid Minakhin, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 11
Co‐Expression of Dominant‐Negative TGF‐β Receptor 2 Enhances the Therapeutic Efficacy of Novel TREM1/DAP12‐BB‐Based CAR‐T Cells in Solid Tumours
Shujia Zhu, Jianping Hu, Jie Lin, et al.
Immunology (2025)
Open Access | Times Cited: 1
The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review
Mausam Patel, Somaira Nowsheen, Sanjay Maraboyina, et al.
Cell & Bioscience (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 69
The role of cell signaling in the crosstalk between autophagy and apoptosis in the regulation of tumor cell survival in response to sorafenib and neratinib
Laurence Booth, Jane L. Roberts, Paul Dent
Seminars in Cancer Biology (2019) Vol. 66, pp. 129-139
Open Access | Times Cited: 67
Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer
Patrycja Gralewska, Arkadiusz Gajek, Agnieszka Marczak, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 64
Page 1 - Next Page

Scroll to top